S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
South Korean doctors hold massive anti-government rally over medical school recruitment plan
NASDAQ:EDIT

Editas Medicine (EDIT) Stock Price, News & Analysis

$10.53
+0.47 (+4.67%)
(As of 03/1/2024 ET)
Today's Range
$9.97
$11.06
50-Day Range
$7.03
$11.07
52-Week Range
$6.08
$11.91
Volume
2.70 million shs
Average Volume
1.97 million shs
Market Capitalization
$861.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00

Editas Medicine MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.56 Rating Score
Upside/​Downside
42.5% Upside
$15.00 Price Target
Short Interest
Bearish
15.39% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.94
Upright™ Environmental Score
News Sentiment
0.58mentions of Editas Medicine in the last 14 days
Based on 29 Articles This Week
Insider Trading
Selling Shares
$1,123 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.52) to ($2.85) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.77 out of 5 stars

Medical Sector

256th out of 950 stocks

Biological Products, Except Diagnostic Industry

38th out of 152 stocks


EDIT stock logo

About Editas Medicine Stock (NASDAQ:EDIT)

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis 10; autosomal dominant retinitis pigmentosa; and EDIT-301, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

EDIT Stock Price History

EDIT Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
StockNews.com Upgrades Editas Medicine (NASDAQ:EDIT) to Hold
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Editas Medicine (NASDAQ:EDIT) Shares Gap Up After Analyst Upgrade
Q4 2023 Editas Medicine Inc Earnings Call
Here's what Wall Street expects from Editas Medicine's earnings report
Earnings Outlook For Editas Medicine
Editas Medicine Q4 2023 Earnings Preview
Editas Medicine (EDIT) to Release Quarterly Earnings on Wednesday
EDIT Mar 2024 7.000 put
EDIT Mar 2024 12.000 call
Editas Medicine (NASDAQ:EDIT) Downgraded to "Sell" at StockNews.com
See More Headlines
Receive EDIT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Editas Medicine and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
3/02/2024
Next Earnings (Estimated)
5/03/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:EDIT
Fax
N/A
Employees
226
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.00
High Stock Price Target
$20.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+42.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
9 Analysts

Profitability

Net Income
$-220,430,000.00
Net Margins
-196.12%
Pretax Margin
-196.12%

Debt

Sales & Book Value

Annual Sales
$78.12 million
Book Value
$4.27 per share

Miscellaneous

Free Float
79,877,000
Market Cap
$861.46 million
Optionable
Optionable
Beta
2.05
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Gilmore O'Neill (Age 60)
    President, CEO & Director
    Comp: $815.37k
  • Dr. Baisong Mei M.D.
    Ph.D., Senior VP & Chief Medical Officer
  • Dr. Feng Zhang Ph.D.
    Co-Founder & Scientific Advisory Board Member
  • Dr. George McDonald Church Ph.D. (Age 70)
    Co-Founder & Scientific Advisory Board Member
  • Dr. J. Keith Joung M.D.
    Ph.D., Co-Founder & Scientific Advisory Board Member
  • Dr. David R. Liu Ph.D.
    Co-Founder & Scientific Advisory Board Member
  • Mr. Erick J. Lucera C.F.A. (Age 56)
    CPA, CFO & Executive VP
  • Dr. Linda C. Burkly Ph.D.
    Executive VP & Chief Scientific Officer
  • Cristi Barnett
    Corporate Communications & Investor Relations
  • Ms. Charlene Stern J.D.
    Ph.D., Executive VP & General Counsel














EDIT Stock Analysis - Frequently Asked Questions

Should I buy or sell Editas Medicine stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last twelve months. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" EDIT shares.
View EDIT analyst ratings
or view top-rated stocks.

What is Editas Medicine's stock price target for 2024?

9 brokerages have issued 12-month price targets for Editas Medicine's shares. Their EDIT share price targets range from $9.00 to $20.00. On average, they predict the company's share price to reach $15.00 in the next year. This suggests a possible upside of 42.5% from the stock's current price.
View analysts price targets for EDIT
or view top-rated stocks among Wall Street analysts.

How have EDIT shares performed in 2024?

Editas Medicine's stock was trading at $10.13 at the beginning of 2024. Since then, EDIT stock has increased by 3.9% and is now trading at $10.53.
View the best growth stocks for 2024 here
.

When is Editas Medicine's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 3rd 2024.
View our EDIT earnings forecast
.

How were Editas Medicine's earnings last quarter?

Editas Medicine, Inc. (NASDAQ:EDIT) announced its quarterly earnings data on Wednesday, February, 28th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.29. The company had revenue of $60 million for the quarter, compared to analysts' expectations of $4.84 million. Editas Medicine had a negative trailing twelve-month return on equity of 42.95% and a negative net margin of 196.12%. Editas Medicine's revenue was up 817.4% compared to the same quarter last year. During the same period last year, the business posted ($0.88) EPS.

What other stocks do shareholders of Editas Medicine own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Micron Technology (MU), Intellia Therapeutics (NTLA), Block (SQ), Advanced Micro Devices (AMD), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO) and Skyworks Solutions (SWKS).

When did Editas Medicine IPO?

(EDIT) raised $100 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.

Who are Editas Medicine's major shareholders?

Editas Medicine's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (10.36%), Dimensional Fund Advisors LP (2.93%), Northern Trust Corp (1.07%), Charles Schwab Investment Management Inc. (0.84%), Nuveen Asset Management LLC (0.79%) and Point72 Asset Management L.P. (0.71%). Insiders that own company stock include Baisong Mei, Bruce Eaton, Gilmore Neil O'neill, James C Mullen, Lisa Anne Michaels, Mark S Shearman and Michelle Robertson.
View institutional ownership trends
.

How do I buy shares of Editas Medicine?

Shares of EDIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EDIT) was last updated on 3/3/2024 by MarketBeat.com Staff